Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » First Drug to Reduce Risk of Mortality and Hospitalization in Heart Failure
Clinical Breakthroughs

First Drug to Reduce Risk of Mortality and Hospitalization in Heart Failure

By Melissa RohmanSep 30, 2022
Share
Facebook Twitter Email
Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor and director of the Center for Deep Phenotyping and Precision Therapeutics at the Institute for Augmented Intelligence in Medicine, was a co-author of the clinical trial reports published in Nature Medicine, The New England Journal of Medicine, The Lancet and Circulation.

The drug dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, reduced the risk of cardiovascular-related mortality and hospitalizations in patients with heart failure, regardless of ejection fraction, according to a series of clinical trial reports published in Nature Medicine, The New England Journal of Medicine (NEJM), The Lancet and Circulation.

“Since establishing the world’s first heart failure with preserved ejection fraction program at Northwestern 15 years ago, we have been searching extensively for a treatment that improves symptoms and exercise tolerance, reduces heart failure hospitalizations and lowers cardiovascular mortality. We have finally achieved that goal with SGLT2 inhibitors, which is a major advance for our patients and proves that HFpEF is indeed a treatable medical condition,” said Sanjiv Shah, ’00 MD, the Neil J. Stone, MD, Professor and director of the Center for Deep Phenotyping and Precision Therapeutics at the Institute for Augmented Intelligence in Medicine, who was a co-author of the studies.

SGLT2 inhibitors, which promote glucose, sodium and water excretion from the kidneys, are used to treat patients with diabetes as well as heart failure with reduced ejection fraction (HFrEF), a condition in which the heart’s left ventricle doesn’t pump enough blood to the rest of the body and the ejection fraction is less than 40 percent. However, the clinical benefits of SGLT2 inhibitors for patients with higher ejection fractions — particularly those with ejection fraction greater than 60 percent— had remained less well known.

In a trial published in The Lancet, a team of investigators performed a meta-analysis of two large-scale heart failure clinical trials — DELIVER, which was published in NEJM, and EMPEROR-Preserved — which included patients with mildly reduced or preserved ejection fraction who received dapagliflozin or placebo. Shah is an executive committee member for the DELIVER trial, the largest-ever randomized clinical trial in heart failure with preserved ejection fraction (HFpEF) to date.

This analysis also included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and hospitalized patients with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF).

Overall, the authors found that dapagliflozin reduced the risk of mortality and hospitalizations for heart failure in a wide range of patients with heart failure across the spectrum of ejection fraction.

These findings were also replicated in a study published in Nature Medicine, in which investigators examined patient outcomes from two clinical trials (DAPA-HF and DELIVER), both of which enrolled participants with heart failure and different ranges of left ventricular ejection fraction.

Additionally, a study published in Circulation examined the efficacy and tolerability of dapagliflozin in relation to frailty in patients enrolled in the DELIVER trial who had mildly reduced and preserved ejection fraction. This study found that dapagliflozin improved health-related quality of life earlier and to a greater extent in patients who were more frail compared to those who were less frail.

Last year, Northwestern investigators were part of a team who published a randomized clinical trial which demonstrated that dapagliflozin improved symptoms, quality of life and exercise capacity in patients with HFpEF, further solidifying the beneficial effects of SGLT2 inhibitors in HFpEF.

“Despite SGLT2 inhibitors, patients with HFpEF are still symptomatic and are at risk for adverse outcomes. We continue to push the envelope with our large group of investigators engaged in HFpEF at Northwestern by leading cutting edge observational studies and clinical trials, with the hope of continuing to improve the lives of our patients,” Shah said.

The DAPA-HF and DELIVER trials were supported by AstraZeneca.

Cardiology Medicine Research
Share. Facebook Twitter Email

Related Posts

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Comments are closed.

Latest News

Weintraub Appointed to Illinois Supreme Court Commission on Elder Law

Mar 28, 2023

Investigating Protein’s Role in Hearing Loss

Mar 27, 2023

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.